Covid-19 roundup: Moderna's stock plunges after lower sales forecast is revealed; Regeneron sees $804M in Q3 monoclonal antibody sales

Moderna’s stock $MRNA plunged more than 14% in premarket trading on Thursday after the biotech cut its end-of-year vaccine sales forecast.

According to its Q3 …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Mod­er­na's stock plunges af­ter low­er sales fore­cast is re­vealed; Re­gen­eron sees $804M in Q3 mon­o­clon­al an­ti­body sales